This work was supported by the Office of Tourism, Trade, and Economic Development of Florida.

1. Preparation of Effector CD8+ T Cells
<ol>
	<li>Thaw autologous cryopreserved PBMCs (2-3 vials of 50&#160;x 106 cells) by transferring the cryovial from liquid nitrogen to a 37 &#176;C water bath.</li>
	<li>Wash the cells by filling the tube to 50 ml with complete RPMI (4 mM L-glutamine, and 100 U/ml penicillin and streptomycin, supplemented with 10% FBS). Count PBMCs and resuspend cells at a concentration of 5 x 106/ml in complete RPMI.</li>
	<li>Add specific peptide (5 &#181;g/ml) and IL-2 (10 ng/ml) to PBMCs.</li>
	<li>Set-up culture in 96 deep well plate; seed 1 ml of cell suspension to each well.</li>
	<li>After 3 days of culture, replace half of the cell culture medium with fresh complete RPMI.</li>
	<li>After 6 days of culture, collect all PBMCs with multichannel pipette and transfer cells in sterile reservoir.</li>
	<li>Count, wash, and resuspend PBMCs at 5 x 107/ml in the recommended separation buffer in 14 ml round bottom tubes. Add human CD8+ T cell enrichment cocktail at 50 &#181;l/ml cells. Mix and incubate at room temperature for 10 min. Add magnetic particles at 150 &#181;l/ml and incubate for 5 min.</li>
	<li>Bring the cell suspension up to 7 ml by adding the separation buffer. Proceed to immunomagnetic isolation of untouched CD8+ T cell by placing the tube into the magnet. After 5 min, with the tube still in the magnet, pour the cells of interest into a new 15 ml conical tube. Take a small aliquot and stain the cells with antibodies against CD3 and CD8 in 1X PBS-2% FBS for 30 min at 4 &#176;C. The purity of the CD8+ T cells can then be measured via flow cytometry with an expected purity of 95% or higher.</li>
	<li>Resuspend CD8+ T cells in 450 &#181;l with complete RPMI.</li>
	<li>Add 225 &#181;l of complete RPMI into 5 screw cap tubes.</li>
	<li>Prepare serial dilutions (from 1:2 to 1:32) by transferring 225 &#181;l of CD8+ to the next tube (see Figure 1 upper panel).</li>
</ol>
2. Preparation of Target CD4+ T Cells
<ol>
	<li>Thaw autologous cryopreserved PBMCs (1 vial of 50 x 106 cells) by transferring the cryovial from liquid nitrogen to a 37 &#176;C water bath.</li>
	<li>Transfer the cell suspension to a 50 ml conical tube containing 10 ml of RPMI.</li>
	<li>Wash cells and resuspend PBMCs at 5 x 107/ml with separation buffer in 14 ml round bottom tubes. Add human CD4+ T cell enrichment cocktail at 50 &#181;l/ml cells. Mix and incubate at room temperature for 10 min. Add magnetic particles at 100 &#181;l/ml and incubate for 5 min at room temperature.</li>
	<li>Bring the cell suspension up to 7 ml by adding separation buffer. Proceed to the isolation of CD4+ T cells by placing the tube into the magnet. After 5 min, with the tube still within the magnet, pour the desired cells into a new 15 ml conical tube. Take a small aliquot and stain the cells with antibodies against CD3 and CD4 in 1x&#160;PBS-2% FBS for 30 min at 4 &#176;C. The purity of the CD4+ T cells can then be measured via flow cytometry with an expected purity of 95% or higher.</li>
	<li>Count CD4+ T cells, split them into two 15 ml conical tubes and wash in warm 1x&#160;PBS.</li>
	<li>Prepare a 0.4 &#181;M CFSE-high working solution in warm PBS.</li>
	<li>Prepare a 0.04 &#181;M CFSE-low working solution by diluting a portion of the 10x&#160;CFSE high working solution in warm PBS.</li>
	<li>Resuspend cells at 20 x 106/ml of PBS (if the number of CD4+ T cells is less than 10 x 106/ml resuspend cells in 0.5 ml of PBS) and stain half of the CD4+ T cells by adding one equal volume of 0.4 &#181;M CFSE-high working solution (final concentration 0.2 &#181;M). For example, for 1 ml of cells, add 1 ml of the CFSE working solution. Stain the remaining half of the CD4+ by adding one equal volume of 0.04 &#181;M CFSE-low working solution (final concentration 0.02 &#181;M). Stain cells for 15 min at 37 &#176;C in 5% CO2 atmosphere.</li>
	<li>After the incubation, pellet cells at 1,500 rpm for 5 min and resuspend in 1 ml of warm complete RPMI to quench the labeling reaction.</li>
	<li>Pulse CFSE-low CD4+ T cells by adding the peptide of interest at a final concentration of 5 &#181;g/ml in the complete RPMI and incubate for 45 min in 5% CO2 atmosphere at 37 &#176;C.</li>
	<li>Wash CFSE-high and CFSE-low CD4+ T cells in complete RPMI. Repeat for a total of two washes. Resuspend at a concentration of 2 x&#160;105 cells/ml each in complete RPMI.</li>
	<li>Mix the two target populations at a ratio of 1:1 (CFSE-High:CFSE-Low) (see Figure 1 lower panel).</li>
</ol>
3. Coculture
<ol>
	<li>From each dilution of CD8+ T cells, seed 100 &#181;l in duplicate to round-bottom 96-well plate.</li>
	<li>Add the mixed target CD4+ T cells (100 &#181;l) to each dilution of effector cells for a final volume of 200 &#181;l.</li>
	<li>To measure the basal apoptosis, seed 3 wells with targets cells alone.</li>
	<li>Incubate coculture for 6 hr in 5% CO2 atmosphere at 37 &#176;C.</li>
</ol>
4. Flow Cytometry Staining and Acquisition
<ol>
	<li>Transfer cells to a V-bottom 96-well plate and stain with PE-conjugated pMHC tetramers for 15 min in 5% CO2 atmosphere at 37 &#176;C.</li>
	<li>Wash in 1x&#160;PBS-2% FBS and stain cells with Far Red LIVE/DEAD fixable dead cell, &#945;CD3-Alexa700, &#945;CD8-Percp, &#945;CD4-Brilliant Violet 650 for 30 min at 4 &#176;C, protected from light.</li>
	<li>Wash cells once with 1x&#160;PBS-2% FBS and resuspend in 100 &#181;l with 2% formaldehyde in 1x&#160;PBS.</li>
	<li>Acquire cells on flow cytometer.</li>
</ol>

<ol>
	<li>Appay, V., Van Lier, R. A. W., Sallusto, F., Roederer, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Cytometry. 73, 975-983 (2008).</li><li>Betts, M. R., Harari, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phenotype+and+function+of+protective+T+cell+immune+responses+in+HIV.">Phenotype and function of protective T cell immune responses in HIV.</a> Curr. Opin. HIV AIDS. 3, 349-355 (2008).</li><li>Roder, J. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+new+immunodeficiency+disorder+in+humans+involving+NK+cells.">A new immunodeficiency disorder in humans involving NK cells.</a> Nature. 284, 553-555 (1980).</li><li>Barber, D. L., Wherry, E. J., Ahmed, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cutting+edge:+rapid+in+vivo+killing+by+memory+CD8+T+cells.">Cutting edge: rapid in vivo killing by memory CD8 T cells.</a> J. Immunol. 171, 27-31 (2003).</li><li>Byers, A. M., Kemball, C. C., Moser, J. M., Lukacher, A. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cutting+edge:+rapid+in+vivo+CTL+activity+by+polyoma+virus-specific+effector+and+memory+CD8++T+cells.">Cutting edge: rapid in vivo CTL activity by polyoma virus-specific effector and memory CD8+ T cells.</a> J. Immunol. 171, 17-21 (2003).</li><li>Devevre, E., Romero, P., Mahnke, Y. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=LiveCount+Assay:+concomitant+measurement+of+cytolytic+activity+and+phenotypic+characterisation+of+CD8(+)+T-cells+by+flow+cytometry.">LiveCount Assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) T-cells by flow cytometry.</a> J. Immunol. Methods. 311, 31-46 (2006).</li><li>Altman, J. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phenotypic+analysis+of+antigen-specific+T+lymphocytes.">Phenotypic analysis of antigen-specific T lymphocytes.</a> Science. 274, 94-96 (1996).</li><li>Mbitikon-Kobo, F. M., Bonneville, M., Sekaly, R. P., Trautmann, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Ex+vivo+measurement+of+the+cytotoxic+capacity+of+human+primary+antigen-specific+CD8+T+cells.">Ex vivo measurement of the cytotoxic capacity of human primary antigen-specific CD8 T cells.</a> J. Immunol. Methods. 375, 252-257 (2012).</li><li>Bryant, J., Day, R., Whiteside, T. L., Herberman, R. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Calculation+of+lytic+units+for+the+expression+of+cell-mediated+cytotoxicity.">Calculation of lytic units for the expression of cell-mediated cytotoxicity.</a> J. Immunol. Methods. 146, 91-103 (1992).</li><li>Varadarajan, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+high-throughput+single-cell+analysis+of+human+CD8(+)+T+cell+functions+reveals+discordance+for+cytokine+secretion+and+cytolysis.">A high-throughput single-cell analysis of human CD8(+) T cell functions reveals discordance for cytokine secretion and cytolysis.</a> J. Clin. Invest. 121, 4322-4331 (2011).</li><li>Trautmann, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Profound+metabolic,+functional,+and+cytolytic+differences+characterize+HIV-specific+CD8+T+cells+in+primary+and+chronic+HIV+infection.">Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection.</a> Blood. 120, 3466-3477 (2012).</li><li>Hildemann, S. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=High+Efficiency+of+Antiviral+CD4(+)+Killer+T+Cells.">High Efficiency of Antiviral CD4(+) Killer T Cells.</a> PLoS One. 8, (2013).</li></ol>

The authors declare that they have no competing financial interests.

The assay described here allows for the quantification of the principal function of CD8+ T cells: the cytolytic activity. The accurate measurement of this function is of paramount importance when characterizing effector functions of CD8+ T cells, as previous studies reported discordance between this function and the cytokine secretion of antigen-specific CD8+ T cells10,11. Due to the short coculture incubation time (6 hr) and the use of autologous target cells, there is low rate of nonspecific killing of targe...

Cytolytic activity is the major function of CD8+ T cells but is still rarely measured as assays used for this purpose are cumbersome and have been difficult to standardize. Accurate measurement of this function is of paramount importance when characterizing effector functions of CD8+ T cells, as no reliable predictors of effective cell-mediated cytotoxicity have been described yet1,2. Here, we propose a new functional assay to measure the cytotoxic activity of antigen-specific CD8+ T cells on target CD4+ T cells. Several approaches have been developed to provide alternatives to the gold standard, chromium release assay. We present here a cell-based assay that reveals the entire process of killing as it measures the death of live target cells. This method was derived from protocols of flow cytometry-based cytotoxic assays in vivo in mice4,5 and in vitro in humans6. In this protocol, the antigen-specific CD8+ T cells contained in the total CD8+ T cell population are used as effector cells and autologous CD4+ T cells are used as target cells. Effector CD8+ T cells of interest are enumerated using MHCI/peptide tetramers7. Death of target cells is calculated by the ratio between peptide loaded/nonloaded CD4+ T cells. We have previously shown that this method was reproducible, sensitive, specific and did not depend on the number of effector cells within the total CD8+ T cell population8. By enumerating both the number of effector and target cells in the coculture assay, the intrinsic capacity of CD8+ T cells to kill target cells can be calculated and expressed in lytic units9.

<table border="0" cellpadding="0" cellspacing="0" width="826">
	<colgroup>
		<col />
		<col />
		<col />
	</colgroup>
	<tbody>
		<tr height="21">
			<td height="21" style="height:21px;width:539px;">EasySep Human CD4+ T Cell Enrichment Kit</td>
			<td style="width:132px;">Stem Cell</td>
			<td style="width:155px;">19052</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:539px;">EasySep Human CD8+ T Cell Enrichment Kit</td>
			<td>Stem Cell</td>
			<td>19053</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">CellTrace CFSE Cell Proliferation Kit - For Flow Cytometry</td>
			<td>Invitrogen</td>
			<td>C34554</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Far Red LIVE/DEAD fixable dead cell</td>
			<td>Invitrogen</td>
			<td>L10120</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Alexa Fluor 700 Mouse Anti-Human CD3</td>
			<td>BD</td>
			<td>557943</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Brilliant Violet 650 Anti-Human CD4 Antibody</td>
			<td>Biolegend</td>
			<td>317435</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">PerCP anti-human CD8 Antibody</td>
			<td>Biolegend</td>
			<td>344707</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">RPMI 1640 Medium 1x</td>
			<td>VWR</td>
			<td>10-040-CV</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Penicillin-Streptomycin 100x Solution</td>
			<td>Invitrogen</td>
			<td>15070063</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Fetal Bovine Serum - Gold, Heat Inactivated</td>
			<td>PAA</td>
			<td>A15-252</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">96-well plates; Treated; U-bottom; with lid</td>
			<td>BD Falcon</td>
			<td>353077</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">25 ml sterile polystyrene, individually wrapped reservoirs</td>
			<td>USA Scientific</td>
			<td>2321-2230</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">96-well U-bottom, sterile 2 ml deep well plates</td>
			<td>Thermo Scientific</td>
			<td>275743</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Human IL-2 (v126), research grade</td>
			<td>Miltenyi Biotec</td>
			<td>130-093-096</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">RoboSep Buffer, separation buffer</td>
			<td>Stem cell</td>
			<td>20104</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">15 ml Polypropylene Conical Tube</td>
			<td>BD Falcon</td>
			<td>352097</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">14 ml round bottom tube, polypropylene</td>
			<td>BD Falcon</td>
			<td>352059</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">The Big Easy EasySep Magnet</td>
			<td>Stem cell</td>
			<td>18001</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">PBS 1x</td>
			<td>VWR</td>
			<td>21-040-CV</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">96-well; V-bottom plate with lid</td>
			<td>Fisher</td>
			<td>12-565-481</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Formaldehyde solution, ACS reagent, 37 wt % in H2O</td>
			<td>Sigma-Aldrich</td>
			<td>252549-500ML</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">1.5 ml screw cap microtube, conical</td>
			<td>Sarstedt</td>
			<td>72.692.005</td>
		</tr>
	</tbody>
</table>

cell-based flow cytometry assay to measure cytotoxic activity

Cytolytic activity of CD8+ T cells is rarely evaluated. We describe here a new cell-based assay to measure the capacity of antigen-specific CD8+ T cells to kill CD4+ T cells loaded with their cognate peptide. Target CD4+ T cells are divided into two populations, labeled with two different concentrations of CFSE. One population is pulsed with the peptide of interest (CFSE-low) while the other remains un-pulsed (CFSE-high). Pulsed and un-pulsed CD4+ T cells are mixed at an equal ratio and incubated with an increasing number of purified CD8+ T cells. The specific killing of autologous target CD4+ T cells is analyzed by flow cytometry after coculture with CD8+ T cells containing the antigen-specific effector CD8+ T cells detected by peptide/MHCI tetramer staining. The specific lysis of target CD4+ T cells measured at different effector versus target ratios, allows for the calculation of lytic units, LU30/106 cells. This simple and straightforward assay allows for the accurate measurement of the intrinsic capacity of CD8+ T cells to kill target CD4+ T cells.

The schematic in Figure 1 summarizes the assay. Purified CD8+ T cells (effector cells) were resuspended in 450 &#181;l of complete RPMI and serial dilutions were performed by adding 225 &#181;l of CD8+ T cells to the next tube containing 225 &#181;l of media (upper panel). Purified CD4+ T cells (target cells) were counted, split into two tubes and stained with two different concentrations of CFSE (high and low) as described in the protocol. CFSE-low CD4+ T cells were pulsed with the peptide of interest a...

Watch this Scientific Journal Video about Cell-based Flow Cytometry Assay to Measure Cytotoxic Activity at JoVE.com

Cell-based Flow Cytometry Assay to Measure Cytotoxic Activity

This protocol describes a sensitive, cell-based cytotoxicity assay. By enumerating the decrease in frequency of live target CD4+ T cells in the presence of an increasing number of effector CD8+ T cells, this assay allows for the direct assessment of cytolytic activity of antigen-specific CD8+ T cells.

Cytolytic activity of CD8+ T cells is rarely evaluated. We describe here a new cell-based assay to measure the capacity of antigen-specific CD8+ T cells ...

cell-based-flow-cytometry-assay-to-measure-cytotoxic-activity

Research

JoVE Journal

Immunology and Infection

17.8K Views.  Vaccine and Gene Therapy Institute of Florida. This protocol describes a sensitive, cell-based cytotoxicity assay. By enumerating the decrease in frequency of live target CD4+ T cells in the presence of an increasing number of effector CD8+ T cells, this assay allows for the direct assessment of cytolytic activity of antigen-specific CD8+ T cells.